EQS-Adhoc: Fresenius Medical Care AG : Fresenius Medical Care reports operating income excluding special items to be above market expectations in Q2 2026 and confirms its outlook for the financial year 2026
|
EQS-Ad-hoc: Fresenius Medical Care AG / Key word(s): Results / Quarter Fresenius Medical Care AG reports financial results for the second quarter of 2026 (unaudited) above market expectations.
Operating income excluding special items amounts to EUR 569 million, up 23% (at constant currency) compared to prior year, driven by stronger operating income growth in the Care Delivery segment than expected by the capital market. This value is above market expectation (consensus) of EUR 515 million. Group revenue increased by 4% (at constant currency) to EUR 4,861 million compared to prior year. This value is slightly above capital market expectations (consensus) of EUR 4,792 million. The company confirms its unchanged financial outlook for the full year 2026. Note: Revenue and operating income, as referred to in the outlook, are both on a constant currency basis and excluding special items. Special items will capture effects that are unusual in nature and have not been foreseeable or not foreseeable in size or impact at the time of providing the outlook. These items are excluded to ensure comparability of the figures presented with the company’s financial targets which have been defined excluding special items. Growth is measured year-on-year. The outlook assumes current laws/policies/regulations and tariffs. Details are disclosed in the reconciliation tables in the press release and financial tables document of the financial reporting for the 2nd quarter of 2026, to be published immediately after publication of this ad hoc announcement on the company’s website. Contact: Dr. Dominik K. Heger Executive Vice President Global Head of Investor Relations, Market & Competition, Sustainability & Head of Investor Relations Fresenius Medical Care AG Else-Kroener-Strasse 1, 61352 Bad Homburg v.d. Hoehe, Germany P +49 6172 2685822 Dominik.Heger@FreseniusMedicalCare.com www.FreseniusMedicalCare.com End of Inside Information
03-Aug-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Fresenius Medical Care AG |
| Else-Kröner-Straße 1 | |
| 61352 Bad Homburg | |
| Germany | |
| Phone: | +49 (0) 6172- 609 2525 |
| Fax: | +49 (0) 6172- 609 2301 |
| E-mail: | ir@freseniusmedicalcare.com |
| Internet: | www.freseniusmedicalcare.com |
| ISIN: | DE0005785802 |
| WKN: | 578580 |
| Indices: | DAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX; NYSE, Luxembourg Stock Exchange |
| LEI Code: | 549300CP8NY40UP89Q40 |
| EQS News ID: | 2376552 |
| End of Announcement | EQS News Service |
|
|
2376552 03-Aug-2026 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | ||
| Sales1 | 17.859,06 | 17.618,69 | 19.398,02 | 19.453,62 | 19.335,91 | 19.627,60 | 19.710,00 | |
| EBITDA1,2 | 4.090,31 | 3.475,97 | 3.350,00 | 3.121,41 | 3.134,65 | 3.327,45 | 3.380,00 | |
| EBITDA-Margin3 | 22,90 | 19,73 | 17,27 | 16,05 | 16,21 | 16,95 | 17,15 | |
| EBIT1,4 | 2.304,41 | 1.852,29 | 1.511,76 | 1.369,44 | 1.392,39 | 1.827,04 | 1.845,00 | |
| EBIT-Margin5 | 12,90 | 10,51 | 7,79 | 7,04 | 7,20 | 9,31 | 9,36 | |
| Net Profit (Loss)1 | 1.435,83 | 1.219,03 | 894,33 | 732,46 | 740,87 | 1.191,27 | 1.230,00 | |
| Net-Margin6 | 8,04 | 6,92 | 4,61 | 3,77 | 3,83 | 6,07 | 6,24 | |
| Cashflow1,7 | 4.233,16 | 2.489,50 | 2.167,38 | 2.628,80 | 2.386,14 | 2.681,00 | 2.740,00 | |
| Earnings per share8 | 3,96 | 3,31 | 2,30 | 1,70 | 1,83 | 3,36 | 3,29 | |
| Dividend per share8 | 1,34 | 1,35 | 1,12 | 1,19 | 1,44 | 1,49 | 1,54 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: PricewaterhouseCoopers
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Fresenius Medical Care | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| 578580 | DE0005785802 | AG | 12.047,81 Mio € | 02.10.1996 | Halten | 9F2C6J8F+2R |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 12,97 | 16,65 | 0,78 | 13,09 | 0,93 | 4,49 | 0,61 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 1,19 | 1,44 | 1,49 | 3,32% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 21.05.2026 | 05.05.2026 | 04.08.2026 | 03.11.2026 | 13.03.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +11,72% | +11,66% | +10,06% | +3,65% | +105,59% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
